Cargando…

Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy

Detalles Bibliográficos
Autores principales:	Heming, Michael, Wiendl, Heinz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962916/ https://www.ncbi.nlm.nih.gov/pubmed/36719925 http://dx.doi.org/10.1073/pnas.2221544120

Ejemplares similares

Immunopathogenesis of multiple sclerosis
por: Racke, Michael K.
Publicado: (2009)

Update on immunopathogenesis and immunotherapy in multiple sclerosis
por: Selter, Rebecca C, et al.
Publicado: (2013)

MULTIPLE SCLEROSIS: NEW ASPECTS OF IMMUNOPATHOGENESIS
por: Lazibat, Ines, et al.
Publicado: (2018)

Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
por: de Sèze, Jérôme, et al.
Publicado: (2023)

An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis
por: Garg, Neeta, et al.
Publicado: (2015)

T cells as the hoped-for savior for SARS-CoV-2 vaccination during CD20-depleting antibody therapy?: Commentary for: “Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.”
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Initial Immunopathogenesis of Multiple Sclerosis: Innate Immune Response
por: Hernández-Pedro, Norma Y., et al.
Publicado: (2013)

SARS-CoV-2 vaccination in multiple sclerosis: A clearer picture for the time point during CD20 depleting therapy
por: Schulte, Eva C., et al.
Publicado: (2021)

Comprehensive Assessment of Multiple Sclerosis: From Immunotherapy and Immunopathogenesis to Predictive Biomarkers
por: Vazifedoust, Soheil, et al.
Publicado: (2022)

Immunopathogenesis of Juvenile Systemic Sclerosis
por: Stevens, Anne M., et al.
Publicado: (2019)

Anti-CD20 therapies for multiple sclerosis: current status and future perspectives
por: Margoni, Monica, et al.
Publicado: (2021)

Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis
por: Bar-Or, Amit, et al.
Publicado: (2021)

Anti-CD20 therapy depletes activated myelin-specific CD8(+) T cells in multiple sclerosis
por: Sabatino, Joseph J., et al.
Publicado: (2019)

The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
por: Hauser, Stephen L., et al.
Publicado: (2023)

Current perspectives on the immunopathogenesis of systemic sclerosis
por: Fuschiotti, Patrizia
Publicado: (2016)

COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies
por: Meca-Lallana, Virginia, et al.
Publicado: (2020)

Molecular Mechanisms of Immunosenescene and Inflammaging: Relevance to the Immunopathogenesis and Treatment of Multiple Sclerosis
por: Perdaens, Océane, et al.
Publicado: (2022)

Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions
por: Wiendl, Heinz, et al.
Publicado: (2021)

What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?
por: Krämer, Julia, et al.
Publicado: (2022)

Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
por: Florou, Despoina, et al.
Publicado: (2020)

Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
por: Roach, Charles A., et al.
Publicado: (2021)

Exploring the Clinical Features, Immunopathogenesis and Approach to Diagnosis for Generalized Pustular Psoriasis [Podcast]
por: Bhutani, Tina, et al.
Publicado: (2023)

Immunopathogenesis of hidradenitis suppurativa and response to anti–TNF-α therapy
por: Lowe, Margaret M., et al.
Publicado: (2020)

Immunopathogenesis of hidradenitis suppurativa and response to anti–TNF-α therapy
por: Lowe, Margaret M., et al.
Publicado: (2022)

Targeting Autophagy in Dendritic Cells as a Mechanism to Limit Immunopathogenesis in Herpetic Stromal Keratitis
por: Blaho, John A.
Publicado: (2016)

Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill
por: Avasarala, Jagannadha
Publicado: (2017)

Anti‐CD20 therapeutic options in immune‐mediated thrombotic thrombocytopenic purpura
por: Maitta, Robert W.
Publicado: (2022)

Immunopathogenesis and immunomodulatory therapy for myocarditis
por: He, Wu, et al.
Publicado: (2023)

Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs—A Systematic Review
por: Rolfes, Leoni, et al.
Publicado: (2019)

Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: Gene expression and protein profiles
por: Fong, Chloe C., et al.
Publicado: (2023)

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes”
por: Rolfes, Leoni, et al.
Publicado: (2021)

Myelin-Specific Cd8 T Cells in the Pathogenesis of Experimental Allergic Encephalitis and Multiple Sclerosis
por: Steinman, Lawrence
Publicado: (2001)

Role of IL-16 in CD4(+) T cell-mediated regulation of relapsing multiple sclerosis
por: Skundric, Dusanka S, et al.
Publicado: (2015)

Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis
por: Wiendl, Heinz, et al.
Publicado: (2015)

Severe Neuroinvasive West Nile Virus in Association With Anti-CD20 Monotherapy for Multiple Sclerosis
por: Thebault, Simon, et al.
Publicado: (2023)

Corrigendum: Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: gene expression and protein profiles
por: Fong, Chloe C., et al.
Publicado: (2023)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
por: Ruck, Tobias, et al.
Publicado: (2015)

Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis
por: Saidha, Shiv, et al.
Publicado: (2023)

Immunopathogenesis of Asthma
por: Platts-Mills, Thomas A.E., et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_3c1csnl46dkot5vee05cegmcvf